Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Anebulo Pharmaceuticals Inc
NASDAQ ANEB
Data sourced from
and
and
Anebulo Pharmaceuticals Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2024
Anebulo Pharmaceuticals Inc Working Capital To Sales Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ANEB
| CEO | Dr. Joseph F. Lawler M.D., Ph.D. |
| IPO Date | May 7, 2021 |
| Location | United States |
| Headquarters | 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734 |
| Employees | 2 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Key trends
Similar companies
Adagene Inc
NA
NA
Acrivon Therapeutics Inc. Common Stock
NA
NA
Aerovate Therapeutics Inc
NA
NA
AN2 Therapeutics Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email